| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EID3 |
| Uniprot No | Q8N140 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-333aa |
| 氨基酸序列 | MKMDVSVRAA GCSDDLSSGE ADVDPKLLEL TADEEKCRSI RRQYRQLMYC VRQNREDIVS SANNSLTEAL EEANVLFDGV SRTREAALDA RFLVMASDLG KEKAKQLNSD MNFFNQLAFC DFLFLFVGLN WMEGDPDKLS DCDDSIALSF WKAIEKEATS WMVKAETFHF VFGSFKLERS APKPRLEHQK KVRKMEENGN MPTKLQKLDL SSYPEATEKN VERILGLLQT YFRKYPDTPV SYFEFVIDPN SFSRTVENIF YVSFIVRDGF ARIRLDEDRL PILEPMNVNQ MGEGNDSSCH GRKQGVISLT LQEWKNIVAA FEISEAMITY SSY |
| 预测分子量 | 38,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EID3重组蛋白的3篇参考文献示例(注：以下内容为虚构，仅作格式参考，实际文献需通过学术数据库检索)：
---
1. **文献名称**：*Cloning and Functional Characterization of Recombinant EID3 Protein in Cell Cycle Regulation*
**作者**：Smith A, et al.
**摘要**：本研究成功克隆了EID3基因，并在大肠杆菌系统中高效表达重组EID3蛋白，通过体外实验证实其通过抑制CDK2活性参与细胞周期G1/S期调控。
2. **文献名称**：*Structural Insights into EID3 Recombinant Protein and Its Interaction with pRb*
**作者**：Zhang Y, et al.
**摘要**：利用X射线晶体学解析了重组EID3蛋白的三维结构，发现其C端结构域直接结合视网膜母细胞瘤蛋白(pRb)，可能通过调控E2F通路影响细胞分化。
3. **文献名称**：*EID3 Recombinant Protein Suppresses Transcriptional Activity of Nuclear Receptors in Vitro*
**作者**：Johnson R, et al.
**摘要**：通过体外报告基因实验证明，纯化的重组EID3蛋白可显著抑制雌激素受体(ERα)和雄激素受体(AR)的转录活性，提示其在激素相关疾病中的潜在作用。
---
建议通过PubMed、Web of Science或Google Scholar以关键词“EID3 recombinant protein”“EID3 cloning”等检索真实文献。
**Background of EID3 Recombinant Protein**
The EID3 (E1A-like inhibitor of differentiation 3) recombinant protein is a genetically engineered variant derived from the EID3 gene, which belongs to the EID family of transcriptional regulators. EID proteins are known for their role in modulating cellular differentiation and epigenetic regulation by interacting with key transcriptional coactivators, such as p300/CBP (CREB-binding protein), and components of the retinoblastoma (pRB) pathway. EID3. specifically, has been implicated in repressing transcriptional activity by inhibiting the acetyltransferase function of p300/CBP, thereby influencing chromatin remodeling and gene expression.
Originally identified for its homology to the adenovirus E1A protein, EID3 is expressed in various tissues and plays a context-dependent role in cellular processes, including cell cycle progression, differentiation, and apoptosis. Its recombinant form is typically produced in bacterial or mammalian expression systems to ensure proper folding and post-translational modifications, enabling functional studies in vitro or in vivo.
Research on EID3 has gained attention due to its potential involvement in cancer biology. Overexpression of EID3 has been linked to tumorigenesis by suppressing tumor suppressor pathways, such as p53 and pRB, and promoting uncontrolled cell proliferation. Conversely, its downregulation may impair cellular differentiation, contributing to disease progression. The recombinant EID3 protein serves as a critical tool for elucidating these mechanisms, facilitating structural analysis, binding assays, and drug discovery efforts targeting EID3-associated pathways.
In summary, EID3 recombinant protein provides a versatile platform for exploring the molecular interplay between transcriptional regulation, epigenetic modifications, and disease, with implications for developing therapeutic strategies in oncology and regenerative medicine.
×
